Duchenne Muscular Dystrophy (DMD) Drugs Market Share To Reach Scalable Heights Of Growth
Duchenne Muscular Dystrophy (DMD) Drugs Industry The global duchenne muscular dystrophy drugs market size is expected to reach USD 9.91 billion by 2030, according to a new report by Grand View Research, Inc., expanding at a CAGR of 16.8% from 2024 to 2030. Several factors such as the emergence of mutation-specific therapies, growing target population, and favorable government initiatives are driving the market. The DMD therapeutics market has only three approved products - Exondys51, Translarna, and Emflaza. Increasing uptake of mutation-targeted therapies is likely to boost the sales of branded drugs. However, stringent regulatory procedures and lack of standardized protocol for the determination of clinical efficacy are key challenges for the market. Exon-skipping platform is estimated to hold about 45.0% of the market share by 2023, driven by increasing adoption of Exondys51 and impending approval of golodirsen and casimersen. Mutation-specific therapies...